Science Explorer Back to mapMap
Institution · MedSIR (Spain)

Most cited papers from MedSIR (Spain)

What are the most cited papers from MedSIR (Spain)?

The most cited paper from MedSIR (Spain) is "ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer" (Alessandra Gennari et al., 2021), with 1,442 citations. Next come "Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer" (780) and "Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial" (754).

Showing 50 of 60 papers. Every paper with more than 32 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Alessandra Gennari et al. · Annals of Oncology Open access 20 Oct 2021 1,442
2 Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer Nicholas C. Turner et al. · New England Journal of Medicine Open access 31 May 2023 780
3 Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial François‐Clément Bidard et al. · Journal of Clinical Oncology Open access 18 May 2022 754
4 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Sara A. Hurvitz et al. · The Lancet Open access 7 Dec 2022 683
5 Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · The Lancet Open access 23 Aug 2023 475
6 Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti et al. · CA A Cancer Journal for Clinicians Open access 12 Nov 2021 390
7 Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez et al. · Neuro-Oncology Open access 26 May 2022 251
8 Efficacy of PI3K inhibitors in advanced breast cancer B. Verret, Javier Cortés, Thomas Bachelot et al. · Annals of Oncology Open access 4 Sep 2019 221
9 Enhancing global access to cancer medicines Javier Cortés, José Manuel Pérez-García, Antonio Llombart‐Cussac et al. · CA A Cancer Journal for Clinicians Open access 18 Feb 2020 206
10 Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial José Manuel Pérez-García et al. · The Lancet Oncology 18 May 2021 166
11 HER2 testing: Current status and future directions Edith A. Perez, Javier Cortés, Ana Maria Gonzalez-Angulo et al. · Cancer Treatment Reviews Open access 11 Sep 2013 163
12 Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status Laura García‐Estévez, Javier Cortés, Silvia Pérez et al. · Frontiers in Oncology Open access 13 Aug 2021 154
13 Immunotherapy for early triple negative breast cancer: research agenda for the next decade Paolo Tarantino, Chiara Corti, Peter Schmid et al. · npj Breast Cancer Open access 18 Feb 2022 148
14 Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial Fátima Cardoso et al. · Nature Medicine Open access 21 Jan 2025 137
15 High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer Marta Palafox et al. · Nature Communications Open access 7 Sep 2022 128
16 Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine Diogo Alpuim Costa, José Guilherme Nobre, Marta Vaz Batista et al. · Frontiers in Microbiology Open access 25 Feb 2021 124
17 Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer Hope S. Rugo, Giampaolo Bianchini, Javier Cortés et al. · ESMO Open Open access Aug 2022 123
18 Targeting FGFR pathway in breast cancer José Manuel Pérez-García, Eva Muñoz‐Couselo, Jesús Soberino et al. · The Breast 20 Nov 2017 113
19 Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer Antonio Llombart‐Cussac et al. · JAMA Oncology Open access 10 Oct 2021 109
20 Targeting brain metastases in breast cancer Chiara Corti, Gabriele Antonarelli, Carmen Criscitiello et al. · Cancer Treatment Reviews 16 Dec 2021 105
21 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial José Manuel Pérez-García et al. · The Lancet Apr 2024 101
22 Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours Maximilian Johannes Mair, Rupert Bartsch, Émilie Le Rhun et al. · Nature Reviews Clinical Oncology ReviewOpen access 21 Apr 2023 97
23 Global unmet psychosocial needs in cancer care: health policy Cristiane Decat Bergerot, Paul B. Jacobsen, William E. Rosa et al. · EClinicalMedicine Open access 16 Nov 2024 89
24 Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer Javier Cortés, Kevin Punie, Carlos H. Barrios et al. · New England Journal of Medicine 19 Oct 2025 85
25 High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study Yasuo Miyoshi, Yuta Yoshimura, Kenichi Saito et al. · Breast Cancer Open access 5 Mar 2020 81
26 Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial Sara A. Hurvitz et al. · ESMO Open Open access 24 Apr 2024 78
27 Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy‐mediated drug resistance in ovarian cancer cells, xenografts, and patient‐derived xenograft models Janice M. Santiago‐O’Farrill, S. John Weroha, Xiaonan Hou et al. · Cancer Open access 12 Nov 2019 77
28 Multiple modes of action of eribulin mesylate: Emerging data and clinical implications Javier Cortés, Patrick Schöffski, Bruce A. Littlefield · Cancer Treatment Reviews Open access 20 Aug 2018 76
29 Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis Guilherme Nader Marta, Marta Monteforte, Elisa Agostinetto et al. · ESMO Open ReviewOpen access Mar 2024 75
30 Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality? Andrea Aran, Laia Garrigós, Giuseppe Curigliano et al. · Cancers Open access 31 Mar 2022 70
31 Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer Ramón Palmero, Álvaro Taus, Santiago Viteri et al. · JCO Precision Oncology 11 Jan 2021 65
32 Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges Débora De Melo Gagliato, Antonio Carlos Buzaid, José Manuel Pérez-García et al. · BioDrugs Sep 2020 65
33 Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis Viola Salvestrini et al. · Radiotherapy and Oncology ReviewOpen access 10 Jul 2023 59
34 TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer Rebecca Alexandra Dent, David W. Cescon, Thomas Bachelot et al. · Future Oncology Open access Aug 2023 58
35 Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma Silvia González-Martínez, Belén Perez‐Mies, Irene Carretero‐Barrio et al. · Cancers Open access 8 Jul 2020 55
36 Translating neoadjuvant therapy into survival benefits: one size does not fit all Leticia De Mattos‐Arruda, Ronglai Shen, Jorge Sergio Reis-Filho et al. · Nature Reviews Clinical Oncology ReviewOpen access 22 Mar 2016 55
37 Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer Masato Takahashi, Javier Cortés, Rebecca Alexandra Dent et al. · JAMA Network Open Open access 15 Nov 2023 54
38 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Fabrice André, Javier Cortés, G. Curigliano et al. · Annals of Oncology Open access 5 Sep 2024 48
39 A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial Antonio Llombart‐Cussac, Xavier B. Pivot, Laura Biganzoli et al. · The Breast Open access 18 Jul 2014 47
40 NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer Samuel A. Jacobs et al. · Breast Cancer Research Open access Dec 2019 46
41 The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós et al. · Med Open access 11 Sep 2024 45
42 Multi-scale urban data models for early-stage suitability assessment of energy conservation measures in historic urban areas Aitziber Egusquiza, Iñaki Prieto, José Luis Izkara et al. · Energy and Buildings Open access 12 Jan 2018 45
43 Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial Mafalda Oliveira et al. · The Lancet Oncology 27 Aug 2024 43
44 A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors Glenn J. Hanna et al. · Cancer Research Communications Open access 23 Aug 2023 43
45 Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World Mayank A Patel, Isabel Tena, Abhishek Jha et al. · Frontiers in Endocrinology Open access 29 Mar 2021 42
46 Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial José Manuel Pérez-García, Antonio Llombart‐Cussac, María Gión et al. · European Journal of Cancer 29 Mar 2021 41
47 Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA David Paul Carbone et al. · ESMO Open Open access 29 May 2025 40
48 Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study Rebecca Alexandra Dent, Javier Cortés, Lajos Pusztai et al. · JNCI Journal of the National Cancer Institute Open access 21 Jun 2024 40
49 Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019 Serena Di Cosimo, Andrea Malfettone, José Manuel Pérez-García et al. · European Journal of Cancer Open access 3 Jun 2020 40
50 Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial Joan Albanell et al. · Clinical Cancer Research Open access 27 Sep 2022 39

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.